ClinicalTrials.gg
WithdrawnNCT02258009TIDE DMEUpdated Oct 27, 2016

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

A Phase 4 interventional study of Ranibizumab and Aflibercept in Visual Impairment Due to Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Withdrawn at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
84th of 91
0 · median 50
Started
2015
with 8 others
Phase 4
26 of 91
none open now
Registered
64th of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 84th largest by enrollment, is one of 9 that started in 2015, is one of 26 in phase 4, and was the 64th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in DME patients in a detailed time course.

03

Conditions studied

  • Visual Impairment Due to Diabetic Macular Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or Type 2 diabetes mellitus
  • Visual impairment predominantly due to DME.

Exclusion criteria

Exclusion Criteria:

  • Stroke or myocardial infarction less than 3 months prior to screening.
  • Presence of uncontrolled systolic blood pressure or diastolic blood pressure
  • Renal failure requiring dialysis or renal transplant or renal insufficiency
  • Untreated diabetes mellitus
  • Use of any systemic anti-VEGF drugs
  • Use of systemic or inhaled for at least 30 consecutive days within 3 months prior to screening.
  • Women who are pregnant or breast feeding or who are menstruating and capable of becoming pregnant* and not practicing a medically approved method of

For either eye:

  • Any active periocular or ocular infection or inflammation
  • Uncontrolled glaucoma
  • Neovascularization of the iris or neovascular glaucoma
  • History of treatment with any anti-angiogenic drugs

For study eye:

  • Atrophy or fibrosis involving the center of the fovea at the time of screening or baseline.
  • Cataract (if causing significant visual impairment), planned cataract surgery during the study period, vitrectomy, aphakia, glaucoma surgery, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization or macular edema of any other cause than DME
  • Irreversible structural damage within 0.5 disc diameter of the center of the macula
  • Panretinal laser photocoagulation within 6 months prior to randomization.
  • Focal/grid laser photocoagulation within 3 months prior to randomization.
  • Any intraocular procedure (including cataract surgery, Yttrium-Aluminum-Garnet capsulotomy) within 3 months prior to baseline or anticipated within the next 6 months following
  • Topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening.
  • Application of intravitreal corticosteroids in vitreous within 6 months prior to screening. Prior application of fluocinolonacetonid releasing implant in vitreous within 36 months prior to screening.

For fellow eye

  • Retinal or choroidal neovascularization or macula edema of any cause

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1

    Monthly intravitreal injections of 0.5 mg ranibizumab

    Drug: Ranibizumab

  • Experimental
    Group 2

    Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab

    Drug: Ranibizumab · Drug: Aflibercept

Interventions

  • 0.5 mg intravitreal injections

    Also known as: Lucentis

  • 2 mg intravitreal injections

    Also known as: Eylea

06

What researchers measure

Primary outcomes

  1. Systemic VEGF-A protein levels

    Systemic VEGF-A protein levels following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept (Area under the curve)

    Time frame: From baseline to study week 12

Secondary outcomes

  1. Systemic VEGF-A protein levels

    Systemic VEGF-A protein levels in patients switching from monthly 2 mg aflibercept injections to monthly 0.5 mg ranibizumab compared to patients treated with 0.5 mg ranibizumab from baseline

    Time frame: From study week 12 to 24

  2. Systemic VEGF-A levels

    Adjustment of systemic VEGF-A levels of patients switching from aflibercept to ranibizumab to levels comparable to baseline or to levels comparable as in patients treated from baseline with ranibizumab

    Time frame: From study week 12 to 24

07

Study locations

1 site
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 7, 2014
Start
Oct 2015
Primary completionEst.
Oct 2016
CompletionEst.
Oct 2016
Last update
Oct 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02258009
Responsible party
Sponsor
First posted
Oct 7, 2014
Start date
Oct 2015
Primary completion
Oct 2016 (estimated)
Completion
Oct 2016 (estimated)
Last update
Oct 27, 2016

Study contacts

Novartis Pharmaceutical
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion